‹ Screener

Apogee Therapeutics, Inc.

APGE · Biological Products, (No Diagnostic Substances) · 58.1M shares · +219%/yr ↑ shares · EDGAR filings ↗

Reference price $132.60 · est. market cap ~$7.7B — last insider sale, 2026-06-22 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)

Grade

D46

Clinical/early-stage biotech — immuno-dermatology clinical, heavy burn ($233M), very cash-rich.

Strengths

Risks

Notable findings

Key metrics

Return on assets
-27.3%
Current ratio
26.6×
Free cash flow
-$233M
Cash & investments
$903M
Cash runway
16q

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2026-06-22HENDERSON MICHAEL THOMASSell80K$132.54
2026-06-22Dambkowski CarlSell26K$132.60
2026-06-10HENDERSON MICHAEL THOMASSell1.1K$84.18
2026-06-10HENDERSON MICHAEL THOMASSell1.6K$85.19
2026-06-10HENDERSON MICHAEL THOMASSell2.3K$86.27
2026-06-10HENDERSON MICHAEL THOMASSell614$86.89
2026-06-10HENDERSON MICHAEL THOMASSell7.7K$82.78
2026-06-10HENDERSON MICHAEL THOMASSell6.8K$82.21
2026-06-03Dambkowski CarlOption exercise4.1K$22.86
2026-06-03Dambkowski CarlSell5.5K$78.71
2026-05-13HENDERSON MICHAEL THOMASSell1.3K$82.58
2026-05-13HENDERSON MICHAEL THOMASSell19K$82.05
2026-05-06Dambkowski CarlOption exercise4.1K$22.86
2026-05-06Dambkowski CarlSell3.7K$83.92
2026-05-06Dambkowski CarlSell1.8K$84.60
2026-05-01Henderson JaneSell811$81.02
2026-05-01Henderson JaneSell900$82.60
2026-05-01Henderson JaneSell289$83.16
2026-04-16HENDERSON MICHAEL THOMASOption exercise3.0K$22.86
2026-04-16Henderson JaneSell2.0K$90.00
2026-04-08HENDERSON MICHAEL THOMASSell18K$82.48
2026-04-08HENDERSON MICHAEL THOMASSell2.0K$83.26
2026-04-08HENDERSON MICHAEL THOMASSell200$85.00
2026-04-01Henderson JaneSell900$84.46
2026-04-01Dambkowski CarlOption exercise4.1K$22.86
2026-04-01Dambkowski CarlSell2.7K$84.31
2026-04-01Dambkowski CarlSell2.7K$85.33
2026-04-01Dambkowski CarlSell100$85.89
2026-04-01Henderson JaneSell1.1K$85.46
2026-03-25Henderson JaneSell2.0K$85.00
2026-03-11HENDERSON MICHAEL THOMASSell8.4K$74.29
2026-03-11HENDERSON MICHAEL THOMASSell8.2K$74.83
2026-03-11HENDERSON MICHAEL THOMASSell3.4K$75.86
2026-03-04Dambkowski CarlOption exercise4.1K$22.86
2026-03-04Dambkowski CarlSell3.2K$70.33
2026-03-04Dambkowski CarlSell2.1K$71.98
2026-03-04Dambkowski CarlSell200$73.26
2026-03-02Henderson JaneSell300$68.27
2026-03-02Henderson JaneSell300$69.43
2026-03-02Henderson JaneSell994$70.45
2026-03-02Henderson JaneSell406$71.66
2026-02-11HENDERSON MICHAEL THOMASSell11K$62.96
2026-02-11HENDERSON MICHAEL THOMASSell7.6K$63.73
2026-02-11HENDERSON MICHAEL THOMASSell955$64.99
2026-02-04Dambkowski CarlOption exercise4.1K$22.86
2026-02-04Dambkowski CarlSell2.5K$64.88
2026-02-04Dambkowski CarlSell1.4K$65.83
2026-02-04Dambkowski CarlSell1.3K$66.85
2026-02-04Dambkowski CarlSell100$67.88
2026-02-04Dambkowski CarlSell200$68.94
2026-02-02Henderson JaneSell792$65.21
2026-02-02Henderson JaneSell1.1K$66.15
2026-02-02Henderson JaneSell100$66.89
2026-01-22Fairmount Funds Management LLCSell1.8M$76.30
2026-01-14HENDERSON MICHAEL THOMASSell1.9K$82.41
2026-01-14HENDERSON MICHAEL THOMASSell1.4K$78.64
2026-01-14HENDERSON MICHAEL THOMASSell8.5K$79.82
2026-01-14HENDERSON MICHAEL THOMASSell2.4K$81.00
2026-01-14HENDERSON MICHAEL THOMASSell5.4K$83.16
2026-01-14HENDERSON MICHAEL THOMASSell470$83.79
2026-01-07Dambkowski CarlSell3.0K$77.13
2026-01-07Dambkowski CarlSell15K$77.90
2026-01-07Dambkowski CarlSell826$79.04
2026-01-07Dambkowski CarlSell100$80.06
2026-01-07Dambkowski CarlOption exercise14K$22.86
2026-01-06Henderson JaneSell2.0K$80.00
2026-01-02Henderson JaneSell4.1K$75.20
2026-01-02Henderson JaneSell1.9K$74.13
2025-12-19Henderson JaneSell1.5K$80.00
2025-12-10HENDERSON MICHAEL THOMASSell9.4K$74.88
2025-12-10HENDERSON MICHAEL THOMASSell10K$75.79
2025-12-10HENDERSON MICHAEL THOMASSell560$76.58
2025-12-04Henderson JaneSell1.5K$75.00
2025-12-04Dambkowski CarlSell11K$75.00
2025-12-04HENDERSON MICHAEL THOMASSell40K$75.01
2025-11-25Henderson JaneSell1.5K$70.00
2025-11-14Henderson JaneSell2.0K$65.00
2025-11-13HENDERSON MICHAEL THOMASSell15K$63.14
2025-11-13HENDERSON MICHAEL THOMASSell1.8K$63.89
2025-11-13HENDERSON MICHAEL THOMASSell100$64.52
2025-11-13HENDERSON MICHAEL THOMASSell3.3K$61.93
2025-11-11Henderson JaneSell1.0K$60.00
2025-11-05Dambkowski CarlOption exercise8.1K$22.86
2025-11-05Dambkowski CarlSell2.3K$53.62
2025-11-05Dambkowski CarlSell2.2K$54.83
2025-11-05Dambkowski CarlSell5.6K$55.58
2025-11-05Dambkowski CarlSell678$56.51
2025-10-01Dambkowski CarlOption exercise2.4K$22.86
2025-10-01Dambkowski CarlSell5.1K$39.80
2025-09-03Dambkowski CarlSell2.5K$37.82
2025-09-03Dambkowski CarlSell190$38.55
2025-08-06Dambkowski CarlSell2.7K$37.78
2025-07-02Dambkowski CarlOption exercise7.4K$22.86
2025-07-02Dambkowski CarlSell6.4K$44.77
2025-07-02Dambkowski CarlSell2.9K$45.49
2025-07-02Dambkowski CarlSell746$46.26
2025-06-04Dambkowski CarlSell2.7K$36.96
2025-05-07Dambkowski CarlSell2.7K$35.75
2025-04-02Dambkowski CarlSell2.5K$35.56
2025-04-02Dambkowski CarlSell500$37.03
2025-04-02Dambkowski CarlSell889$37.59
2025-03-05Dambkowski CarlSell1.6K$30.48
2025-03-05HENDERSON MICHAEL THOMASSell7.3K$29.98
2025-03-05HENDERSON MICHAEL THOMASSell2.7K$30.62
2025-02-05Dambkowski CarlOption exercise795$22.86
2025-02-05Dambkowski CarlSell3.5K$40.69
2025-02-05HENDERSON MICHAEL THOMASSell15K$40.58
2025-01-31HENDERSON MICHAEL THOMASOption exercise8.5K$22.86
2025-01-08HENDERSON MICHAEL THOMASSell12K$48.72
2025-01-08HENDERSON MICHAEL THOMASSell2.9K$49.38
2025-01-02Dambkowski CarlOption exercise1.4K$22.86
2025-01-02Dambkowski CarlSell1.5K$46.42
2025-01-02Dambkowski CarlSell2.5K$47.21
2025-01-02Dambkowski CarlSell100$47.92

All non-derivative Form 4 activity (SEC), newest first.

Clinical trials

TrialTitlePhaseStatusPrimary completion
NCT07003425 ↗A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Atopic Dermatitis
PHASE2Recruiting2029-12-01
NCT07027527 ↗An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
PHASE1Active Not Recruiting2026-12-01
NCT06395948 ↗A Study Evaluating APG777 in Atopic Dermatitis
Atopic Dermatitis
PHASE2Active Not Recruiting2026-11-01
NCT06920901 ↗A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
Asthma
PHASE1Active Not Recruiting2026-09-01

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Notable events (8-K)

DateItems
2026-06-22Material agreementExhibitsfiling ↗
2026-06-22Material agreementShareholder voteReg FDOtherExhibitsfiling ↗
2026-06-12Shareholder votefiling ↗
2026-05-27Material agreementReg FDExhibitsfiling ↗
2026-05-27Reg FDOtherExhibitsfiling ↗
2026-05-11ResultsExhibitsfiling ↗
2026-04-24Exec/director changefiling ↗
2026-03-25Material agreementExhibitsfiling ↗

Recent filings

FormFiledPeriodAccession
8-K2026-06-222026-06-170001140361-26-025841 ↗
8-K2026-06-222026-06-180001140361-26-025844 ↗
8-K2026-06-122026-06-090001193125-26-269650 ↗
8-K2026-05-272026-05-260001104659-26-066575 ↗
8-K2026-05-272026-05-270001104659-26-066572 ↗
8-K2026-05-112026-05-110001193125-26-215683 ↗
10-Q2026-05-112026-03-310001193125-26-215698 ↗
8-K2026-04-242026-04-210001193125-26-177288 ↗
8-K2026-03-252026-03-240001104659-26-034579 ↗
8-K2026-03-232026-03-230001104659-26-032950 ↗
8-K2026-03-022026-03-020001974640-26-000001 ↗
10-K2026-03-022025-12-310001974640-26-000002 ↗